bioMérieux, a global leader in the field of in vitro diagnostics, today announced the closing of the sale of its hemostasis range of products to Trinity Biotech plc.
Need information ?
Contact us
You are here
bioMérieux Sells its Hemostasis Line of Business
bioMérieux contributes to the fight against AIDS in the Democratic Republic of Congo
bioMérieux, the world's third-largest diagnostic company in the field of infectious diseases, has won a new contract ; the company will be the exclusive provider of equipment for measuring HIV viral load in the Democratic Republic of Congo.
bioMérieux NucliSENS® easyMAG™ Receives Technology Innovation of the Year Award from Frost & Sullivan
2006 Technology Innovation Award of the Year in the field of In Vitro Diagnostics. bioMérieux has been the proud recipient of 2006 Technology Innovation of the Year award in the field of in vitro diagnostics. After extensive evaluation, Frost & Sullivan, an industry-leading global growth consulting company, chose bioMérieux for their development of the NucliSENS easyMAG system. The NucliSENS easyMAG is a breakthrough platform based on the company’s proprietary technologies and features premium nucleic acid extraction quality and enhanced productivity through highly accessible instrumentation.
ExonHit and bioMérieux reach an important research milestone in the molecular detection of breast cancer from blood samples
ExonHit Therapeutics, a French drug and diagnostic discovery company, and bioMérieux, a major player in the field of in vitro diagnostics, announce today that they have reached an important research milestone in the diagnosis of breast cancer.
bioMérieux launches an avian flu test for research purposes
As a major player in the field of in vitro diagnostics, bioMérieux confirms its commitment to the fight against emerging diseases and launches its avian flu detection test.
bioMérieux Editions publishes a book on hospital-acquired infections
bioMérieux annonce la parution d’un ouvrage consacré aux Infections Liées aux Soins (ILS). Ce livre a été élaboré par les professeurs Marie-Laure Joly-Guillou et Bernard Régnier. Le Docteur Jean Carlet en a signé la préface.
bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration
bioMérieux and ExonHit announced today that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.